Inflammatory bowel disease (IBD) is associated with immune dysregulation triggered by environmental factors, microbial dysbiosis, and genetical susceptibility. Regulatory T cells (Tregs) are critical in controlling intestinal immune homeostasis and Treg deficiencies trigger intestinal inflammation.[@bib1], [@bib2] Interleukin (IL)-2 is a key cytokine controlling differentiation, survival, and function of Tregs.[@bib3] In contrast to conventional T cells (Tcon), Tregs exhibit higher sensitivity to IL-2 due to constitutive expression of CD25, the high-affinity subunit of the IL-2 receptor.[@bib3] Low-dose (LD) IL-2 has been reported to selectively expand Tregs and used as a therapeutic strategy in chronic graft-versus-host disease, hepatitis C virus--induced vasculitis, systemic lupus erythematosus, and Wiskott-Aldrich syndrome.[@bib4], [@bib5], [@bib6], [@bib7] Thus, we sought to investigate LD IL-2 as an IBD therapeutic using humanized mice.

Similar to other disease settings,[@bib4], [@bib5], [@bib6], [@bib7] LD IL-2 specifically activated peripheral blood and colonic lamina propria Tregs from patients with IBD in vitro ([Supplementary Figure 1](#mmc2){ref-type="supplementary-material"}). To study the efficacy of LD IL-2 in a preclinical setting, we treated NSG mice reconstituted with healthy donor peripheral blood mononuclear cells with phosphate-buffered saline (PBS) or LD IL-2 (1.0 × 10^4^ IU/day \[10K\]; 5.0 × 10^4^ IU/day \[50K\]) ([Figure 1](#fig1){ref-type="fig"}*A*). On day 5 following immune reconstitution, colitis was induced by rectal application of 2,4-dinitrobenzene sulfonic acid. Mice receiving 10K IL-2 had reduced weight loss and reduced histology scores compared with mice treated with PBS or 50K IL-2 ([Figure 1](#fig1){ref-type="fig"}*B* and *C*). Phospho-flow analysis of STAT5 confirmed that 10K IL-2 specifically activated Tregs, whereas STAT5 phosphorylation was also detected in Tcons from mice receiving 50K IL-2 ([Figure 1](#fig1){ref-type="fig"}*D*). Expansion of Tregs was observed in blood, spleen, and colon of mice treated with either dose of IL-2 ([Figure 1](#fig1){ref-type="fig"}*E*). However, reduced body weight loss upon treatment with 10K IL-2 associated with Treg expansion in the absence of significant Tcon activation suggest that a therapeutic range of LD IL-2 is critical ([Figure 1](#fig1){ref-type="fig"}*C*--*E*).Figure 1**Low-dose (LD) interleukin (IL)-2 selectively expands human regulatory T cells (Tregs) in vivo and alleviates experimental colitis.** (*A*) Schematic of low-dose interleukin-2 treatment of 2,4-dinitrobenzene sulfonic acid (DNBS)--induced colitis in NSG mice reconstituted with human peripheral blood mononuclear cells (PBMCs). (*B*) Percent initial body weight and (*C*) histological analysis of distal colons following 3 days post-DNBS enema. With 20× magnification. Scale bars = 100 μm. (*D*) Phospho-flow analysis of pSTAT5 in splenic conventional T cells (Tcons) and Tregs. (*E*) Representative FACS showing Tregs in blood, spleen, and colon. Graphs are pooled data from 5 experiments. 10K, 1.0 × 10^4^ IU/day; 50K, 5.0 × 10^4^ IU/day; PBS = phosphate-buffered saline. ∗*P* \< .05, ∗∗*P* \< .01, ∗∗∗*P* \< .001.

To evaluate the efficacy of LD IL-2 in a fully reconstituted humanized murine system, we developed NSG mice that lack murine MHCII but express human HLA-DQ8 (NSGIIDQ8 mice). Sixteen-week-old mice reconstituted with human healthy donor CD34^+^ hematopoietic stem cells at birth were sensitized with 2,4,6-trinitrobenzenesulfonic acid (TNBS) and treated with 10K IL-2 daily followed by induction of colitis with TNBS rectal challenge ([Figure 2](#fig2){ref-type="fig"}*A*). In contrast to mice treated with PBS, mice receiving LD IL-2 exhibited significant improvement in histological disease activity with a trend in reduced weight loss ([Figure 2](#fig2){ref-type="fig"}*B* and *C*). LD IL-2 was associated with significant expansion of human Tregs in the blood and spleen but not in the mesenteric lymph nodes or colon ([Figure 2](#fig2){ref-type="fig"}*D* and *E*). Correspondingly, no difference in the frequency of FOXP3-expressing T cells was detected using RNAscope analysis of paraffin-embedded colonic lamina propria sections ([Supplementary Figure 2](#mmc2){ref-type="supplementary-material"}). The expansion of peripheral Tregs and improvement in disease activity in LD IL-2-treated mice was not attributed to alterations in the human immune reconstitution between groups ([Figure 2](#fig2){ref-type="fig"}*F*) or frequency of effector T or natural killer cells ([Supplementary Figure 3](#mmc2){ref-type="supplementary-material"}).Figure 2**Low-dose (LD) interleukin (IL)-2 expands human CD45RO**^**+**^**regulatory T cells (Tregs) and ameliorates colitis in humanized mice.** (*A*) Schematic depicting 2,4,6-trinitrobenzenesulfonic acid (TNBS) in NSGIIDQ8 mice reconstituted with CD34^+^ hematopoietic stem cells (HSCs). (*B*) Percent initial body weight and (*C*) representative hematoxylin and eosin--stained distal colon sections with histological colitis scores from 2 independent experiments. With 10× magnification. Scale bars = 200 μm. (*D* and *E*) Representative flow cytometry plots and statistical analysis of human Tregs in blood, spleen, mesenteric lymph node (MLN), and colon. ∗∗*P* \< .01 or ∗∗∗*P* \< .001 compared to control, ^††^*P* \< .01 compared to EtOH, ± *P* \< .001 compared to TNBS. (*F*) Frequency of human CD45^+^ cells in blood and spleen. (*G*) SPADE analysis from 37 analyte CyTOF of splenic CD25^+^ cells from phosphate-buffered saline (PBS)-- and LD IL-2--treated mice. Each circle represents cells with a similar phenotype. Circle size is proportional to the number of cells. Heat color is the median expression value (MEV) of FOXP3 in arcsinh~15~ scale. (*H*) MEV quantified for various activation or functional Treg markers in splenic CD25^+^ cells based on the top 10 nodes of the SPADE analysis within the FOXP3^+^ cells. Data are pooled from 3 independent experiments. ∗*P* \< .05, ∗∗*P* \< .01, ∗∗∗*P* \< .001.

Tregs have been reported to suppress pathogenic effector T cell function and autoimmunity through both contact-dependent and contact-independent mechanisms.[@bib8] CyTOF analysis of splenic CD25^+^ cells showed an increased frequency of FOXP3^+^ T cells in mice receiving LD IL-2 with majority of expanded cells falling within the CD45RO^+^FOXP3^+^ Treg cluster ([Figure 2](#fig2){ref-type="fig"}*G*). The majority of FOXP3^+^ Tregs that expanded after LD IL-2-treatment exhibited increased expression of molecules associated with Treg activation or function (HLA-DR, CD45RO, and CTLA4) or chemokines important for trafficking and migration to sites of inflammation (CCR4 and CCR6) ([Figure 2](#fig2){ref-type="fig"}*H*). Our data suggest that expansion and activation of memory Tregs might be critical clinical determinants.

Taken together, our study demonstrates that LD IL-2 expands Tregs and ameliorates experimental colitis in humanized mice. While these data support a rationale for LD IL-2 in IBD therapy, the safety of long-term drug administration needs further investigation to ensure continued selective activation of Tregs over Tcons. Based on these promising results, we have initiated a phase 1b/2a clinical trial investigating the safety and therapeutic efficacy of LD IL-2 in patients with moderate to severe ulcerative colitis ([NCT02200445](https://clinicaltrials.gov/ct2/show/NCT02200445){#intref0010}).
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